|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CYP1B1 expression in human lung cancer cells are regulated by AhR in 2D and 3D cells.
|
29921510 |
2018 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP1B1 gene polymorphisms appear to influence lung cancer susceptibility.
|
29938532 |
2018 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We observed lower amounts of CYP1B1 occurring in the middle stages of LC, regardless of gender, age or histological type of lung cancer.
|
28858732 |
2017 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
As a result, 15 SNPs on or near 12 genes and one miRNA with strong evidence of association with lung cancer risk were identified, including TERT (rs2736098), CHRNA3 (rs1051730), AGPHD1 (rs8034191), CLPTM1L (rs401681 and rs402710), BAT3 (rs3117582), TRNAA (rs4324798), ERCC2 (Lys751Gln), miR-146a2 (rs2910164), CYP1B1 (Arg48Gly), GSTM1 (null/present), SOD2 (C47T), IL-10 (-592C/A and -819C/T), and TP53 (intron 6).
|
29110844 |
2017 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, significant association was observed between cytochrome P450 1B1 Leu432Val polymorphism and lung cancer risk (dominant model: odds ratio = 1.29, 95% confidence interval = 1.08-1.53; recessive model: odds ratio = 1.21, 95% confidence interval = 1.05-1.39; additive model: odds ratio = 1.43, 95% confidence interval = 1.21-1.69) when all the eligible studies were pooled into the meta-analysis.
|
26283052 |
2016 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, as the gene polymorphisms reflected, the polymorphisms of CYP1A1 (-3801T/C and -4889A/G), CYP1A2 (- 163C/A and -2467T/delT), CYP1B1 (-48G/C, -119G/T and -432G/C), CYP2E1 (-1293G/C and -1053 C/T) have been associated with an increased risk of lung cancer.
|
26652254 |
2015 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Impacts on the catalytic activity of the CYP1B1 enzyme, as well as an association of the Leu432Val polymorphism with the risk of lung cancer, have been described; however, the results remain controversial.
|
24989113 |
2014 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this meta analysis, we assessed 10 case-control studies included 7,067 cases and 9,374 controls of the association between CYP1B1 SNPs of Leu432Val (rs1056836, 432C>G), rs1800440" genes_norm="1545">Asn453Ser (rs1800440, 453A>G), rs1056827" genes_norm="1545">Ala119Ser (rs1056827, 119G>T), Arg48Gly (rs10012, 48C>G) and the risk of lung cancer.
|
21674184 |
2012 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the presence of E(2) within lung tissue when combined with the modulation of cytochrome P450 1b1 and other estrogen metabolism genes by tobacco smoke provides novel insight into a possible role for estrogens in lung cancer.
|
20515954 |
2010 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer risk associated with individual SNPs was seen for GSTP1 [A allele; odds ratio (OR) = 1.85; 95% confidence interval (CI), 1.04-3.27] and XRCC1 (A/A genotype; OR = 1.68; 95% CI, 1.01-2.79) in white women and CYP1B1 (G allele; OR = 11.1; 95% CI, 1.18-104) in black women smokers.
|
19174490 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the CYP1B1 and the CYP2A13 genotypes may contribute to individual susceptibility to early-onset lung cancer in women.
|
19414505 |
2009 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer.
|
18573508 |
2008 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP1A1 is a gene involved in the high aryl hydrocarbon hydroxylase -inducible phenotype, which is a genetically-determined variation among individuals that has been associated with lung cancer risk.
|
18409147 |
2008 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the combination of risk genotypes of CYP1B1 Leu432Val with CYP1A1 Ile462Val was associated with the risk of lung adenocarcinoma (adjusted OR=2.16; 95% CI, 1.02-4.57) as well as overall lung cancer (adjusted OR=2.23; 95% CI 1.01-4.89).
|
17980933 |
2008 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes).
|
17496311 |
2007 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association was seen between lung cancer risk and polymorphisms in CYP1A1 Msp1 or CYP1B1 Leu(432)Val for Caucasians or African Americans, after adjusting for age at diagnosis, sex, pack years of smoking and family history of lung cancer.
|
17174438 |
2007 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a population-based case-cohort study, we have investigated the occurrence of lung cancer in relation to polymorphisms in the phase I gene cytochrome P450 1B1 and in the phase II genes glutathione S-transferase A1, NAD(P)H quinone oxidoreductase and N-acetyltransferase 2 (NAT2).
|
15808404 |
2005 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The combination of CYP1B1 Leu(432)Val and NQO1 C(609)T appeared to be associated with the highest risk of lung cancer (OR = 4.14, 95% CI 1.60-10.74), although no combinations differed significantly from the risk associated with CYP1B1 Leu(432)Val alone.
|
16051642 |
2005 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, stratifying on smoking status demonstrated that CYP1B1 432Val genotype had a slightly combined effect on lung cancer with smoker subjects (OR=2.78, 95%CI=1.46-5.29).
|
15896461 |
2005 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data indicated that CYP1B1 mRNA levels were elevated in peripheral leukocytes of lung cancer patients.
|
15093676 |
2004 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
CTD_human |
Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice.
|
11376689 |
2001 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the association between CYP1B1 genetic polymorphism and breast or lung cancer incidence.
|
10739169 |
2000 |
|
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population.
|
9731718 |
1998 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epidemiologic evidence for the association of aryl hydrocarbon hydroxylase and lung cancer is presently problematic because of difficulties in the assay and subsequent confounding factors.
|
1844821 |
1991 |
|
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three examples of pharmacogenetic risk factors are discussed: the first two are p450 enzymes whose activity has been associated with susceptibility to lung cancer (debrisoquine hydroxylase, aryl hydrocarbon hydroxylase), and the last, N-acetyltransferase, a non-p450 enzyme, has been associated with bladder cancer susceptibility.
|
1820735 |
1991 |